

Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ

Ref: FOI-062024-000916

Date: 13/06/2024

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000.

Request

I am researching the incidence and treatment of breast cancer. I would greatly appreciate if you could answer the following questions.

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Abemaciclib + Fulvestrant
- Alpelisib + Fulvestrant
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide
- Aromatase Inhibitor as a single agent
- Atezolizumab
- Capecitabine as a single agent
- Carboplatin + Paclitaxel
- Eribulin as a single agent or in combination
- Everolimus + Exemestane
- Fulvestrant as a single agent
- Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Palbociclib + Fulvestrant
- Parp Inhibitors (Olaparib/Talazoparib)
- Pembrolizumab
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Ribociclib + Fulvestrant
- Sacituzumab Govitecan
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
- Trastuzumab deruxtecan
- Trastuzumab as a single agent or in combination
- Trastuzumab emtansine
- Any other active systemic anti-cancer therapy

Q2. If breast cancer is not treated at or within the Trust, where are patients referred?

Response

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, Exemestane, Letrozole)	21
Abemaciclib + Fulvestrant	0
Alpelisib + Fulvestrant	0
Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide	42
Aromatase Inhibitor as a single agent	0
Atezolizumab	1
Capecitabine as a single agent	8
Carboplatin + Paclitaxel	2
Eribulin as a single agent or in combination	3
Everolimus + Exemestane	0
Fulvestrant as a single agent	16
Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	0
Palbociclib + Fulvestrant	0
Parp Inhibitors (Olaparib/Talazoparib)	1
Pembrolizumab	7
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	0
Ribociclib + Fulvestrant	0
Sacituzumab Govitecan	6
Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent	42
Trastuzumab deruxtecan	9
Trastuzumab as a single agent or in combination	71
Trastuzumab emtansine	9
Any other active systemic anti-cancer therapy	94

Q2. If breast cancer is not treated at or within the Trust, where are patients referred?

DGFT provides systemic anticancer therapy to treat breast.

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager
Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

**Freedom of Information Team
The Dudley Group NHS Foundation Trust**